Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y, Satouchi M, Katakami N, Fujita S, Kaji R, Hata A, Urata Y, Shimada T, Uchida J, Tomii K, Morita S, Negoro S. Hattori Y, et al. Among authors: morita s. Cancer Chemother Pharmacol. 2014 Jan;73(1):17-23. doi: 10.1007/s00280-013-2290-y. Epub 2013 Oct 20. Cancer Chemother Pharmacol. 2014. PMID: 24141372 Clinical Trial.
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group. Nakajo A, et al. Among authors: morita s. Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4. Cancer Chemother Pharmacol. 2008. PMID: 18317763 Clinical Trial.
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. Inoue A, et al. Among authors: morita s. J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224850 Clinical Trial.
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T. Morita S, et al. Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16. Clin Cancer Res. 2009. PMID: 19531624
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: morita s. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: morita s. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Kunisaki C, Takahashi M, Makino H, Oshima T, Fujii S, Takagawa R, Kimura J, Kosaka T, Ono HA, Akiyama H, Kameda K, Kito F, Morita S, Endo I. Kunisaki C, et al. Among authors: morita s. Cancer Chemother Pharmacol. 2011 Jun;67(6):1363-8. doi: 10.1007/s00280-010-1433-7. Epub 2010 Aug 28. Cancer Chemother Pharmacol. 2011. PMID: 20803016 Clinical Trial.
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K. Okamoto I, et al. Among authors: morita s. J Clin Oncol. 2010 Dec 20;28(36):5240-6. doi: 10.1200/JCO.2010.31.0326. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079147 Clinical Trial.
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M, Takao S, Hirata M, Okamoto Y, Yamashita S, Kawaguchi Y, Takami M, Furusawa H, Morita S, Abe C, Sakamoto J. Yoshimoto M, et al. Among authors: morita s. Cancer Chemother Pharmacol. 2012 Aug;70(2):331-8. doi: 10.1007/s00280-012-1826-x. Epub 2012 Apr 11. Cancer Chemother Pharmacol. 2012. PMID: 22526409 Clinical Trial.
3,578 results